2024
Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails
Springer S. Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails. JAMA Network Open 2024, 7: e2434649. PMID: 39316405, DOI: 10.1001/jamanetworkopen.2024.34649.Peer-Reviewed Original ResearchConsiderations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionSerious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder
Springer S. Serious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder. JAMA Network Open 2024, 7: e2421640. PMID: 39046746, DOI: 10.1001/jamanetworkopen.2024.21640.Peer-Reviewed Original ResearchAdultAnalgesics, OpioidFemaleHumansMaleMiddle AgedOpioid-Related DisordersSubstance Abuse, Intravenous
2023
Integrated Care Models: HIV and Substance Use
Hill K, Kuo I, Shenoi S, Desruisseaux M, Springer S. Integrated Care Models: HIV and Substance Use. Current HIV/AIDS Reports 2023, 20: 286-295. PMID: 37698755, PMCID: PMC11034717, DOI: 10.1007/s11904-023-00667-9.Peer-Reviewed Original ResearchMeSH KeywordsDelivery of Health Care, IntegratedHealth ServicesHIV InfectionsHumansOpioid-Related DisordersConceptsSubstance use disordersUse disordersSubstance useIntegrated careRecent HIV outbreaksHIV viral suppressionMultidisciplinary care teamHIV virologic suppressionOpioid use disorderRisk of HIVHarm reduction programsSubstance use treatmentEvidence-based strategiesVirologic suppressionViral suppressionHIV outbreakCare teamProvider trainingHIVOnward transmissionHealth outcomesCare servicesClinic leadershipCare integrationMedical literatureInpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial
Seval N, Nunez J, Roth P, Schade M, Strong M, Frank C, Litwin A, Levin F, Brady K, Nunes E, Springer S. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal Of Addiction Medicine 2023, 17: e232-e239. PMID: 37579095, PMCID: PMC10368784, DOI: 10.1097/adm.0000000000001136.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansInpatientsMethadoneOpiate Substitution TreatmentOpioid-Related DisordersPainConceptsOpioid use disorderFull agonist opioidsAgonist opioidsHospital dischargeCase seriesSurgical interventionUse disordersCurrent opioid use disorderInfectious disease physiciansLow-dose strategyMulticenter clinical trialPotential surgical interventionLife-threatening infectionsCOMMIT trialComplex hospitalizationsDepot buprenorphineOpioid relapseUnderused medicationsOpioid withdrawalSublingual buprenorphineBuprenorphine dosesDisease physiciansConcurrent painClinical trialsConcurrent infection
2022
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder
Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2022, 142: 108852. PMID: 35988513, PMCID: PMC9509444, DOI: 10.1016/j.jsat.2022.108852.Peer-Reviewed Original ResearchConceptsInjection opioid useOpioid use disorderHepatitis C virusOpioid useXR-NTXOpioid injectionUse disordersDouble-blind placebo-controlled trialExtended-release naltrexonePlacebo-controlled trialCopies/mLIntravenous opioid useTransmission of HIVJustice-involved populationsJustice-involved participantsInjection equipmentHigh treatment groupJustice-involved personsHCV antibodiesHIV RNAPlacebo groupTreat analysisC virusInjection useJustice-involved individualsGender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineFemaleHumansMaleNaltrexoneOpiate Substitution TreatmentOpioid-Related DisordersQuality of LifeSex FactorsConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisordersFactors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidBuprenorphineDrug OverdoseFemaleHumansMaleMethadoneNaltrexoneOpiate Substitution TreatmentOpioid-Related DisordersPainProspective StudiesConceptsOpioid use disorderHigher pain interferenceMOUD retentionPain interferenceUse disordersOngoing prospective cohort studySevere opioid use disorderProspective cohort studyMultivariable logistic regressionCohort of adultsMethadone doseAnalgesic effectBuprenorphine doseCohort studyOpioid useResultsA totalHigher oddsMOUDAdjusted modelHigh doseLogistic regressionBuprenorphineMethadoneDoseDiscontinuationRationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCOVID-19HumansNarcotic AntagonistsOpioid-Related DisordersSARS-CoV-2VeteransConceptsOpioid use disorderVeterans Healthcare AdministrationFormulations of buprenorphineComparative effectiveness trialOpioid useEffectiveness trialUse disordersOpioid epidemicSublingual buprenorphine/naloxoneSevere opioid use disorderBuprenorphine/naloxoneUS opioid epidemicClinical effectiveness trialStandard of careEffective medication treatmentsExtended-release formulationUrgent clinical needLong-term trialsHepatitis BSecondary outcomesSevere sequelaeOpioid abstinencePrimary outcomeMedication treatmentTRIAL REGISTRATION
2021
Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment
Biondi BE, Frank CA, Forray A, Springer SA. Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment. Substance Use & Addiction Journal 2021, 42: 905-911. PMID: 33750285, PMCID: PMC8455717, DOI: 10.1080/08897077.2021.1900984.Peer-Reviewed Original ResearchMeSH KeywordsCriminal LawDelayed-Action PreparationsFemaleHIV InfectionsHumansInjections, IntramuscularMaleNaltrexoneNarcotic AntagonistsOpioid-Related DisordersSex FactorsConceptsSubstance use disordersOpioid use disorderMedication treatmentUse disordersAlcohol use disorderMental health severityXR-NTXAntiretroviral therapyDouble-blind placebo-controlled trialExtended-release naltrexone treatmentExtended-release naltrexonePlacebo-controlled trialCriminal justice-involved personsHealth severityGender differencesCocaine use disorderDrug use severityJustice-involved personsClinical characteristicsART adherenceNaltrexone treatmentTreatment outcomesHigh prevalenceCocaine useHIVLinking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions
Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, Springer SA. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. International Journal Of Drug Policy 2021, 96: 103283. PMID: 34020864, PMCID: PMC8568621, DOI: 10.1016/j.drugpo.2021.103283.Peer-Reviewed Original ResearchConceptsMobile health unitOpioid use disorderHepatitis COUD preventionTreatment servicesInfectious diseasesHepatitis C virus (HCV) managementOpioid use disorder preventionCJ-involved individualsCriminal justice-involved individualsCJ systemHarm reduction servicesImproving HIVCare cascadePatient navigationJustice-involved individualsHealth unitsUse disordersHIVReduction servicesSubstance usePreventionDisorder preventionCommunity agenciesTreatmentLong-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal Of Substance Use And Addiction Treatment 2021, 128: 108389. PMID: 33865691, PMCID: PMC8384640, DOI: 10.1016/j.jsat.2021.108389.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidBuprenorphineDelayed-Action PreparationsHumansInjections, IntramuscularNaltrexoneNarcotic AntagonistsOpioid-Related DisordersConceptsOpioid use disorderSelf-reported opioid useOpioid-positive urine samplesExtended-release buprenorphineExtended-release naltrexoneOpioid overdose eventsXR-NTXOpioid treatmentObservational cohortOpioid useUsual armCare outcomesUse disordersNoninferiority designOverdose eventsUrine samplesBuprenorphineTreatmentAdultsEnhanced treatmentNaltrexoneRCTsCohortU.S. localesTrialsDesign and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder
Seval N, Frank CA, Litwin AH, Roth P, Schade MA, Pavlicova M, Levin FR, Brady KT, Nunes EV, Springer SA. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemporary Clinical Trials 2021, 105: 106394. PMID: 33838307, PMCID: PMC8172465, DOI: 10.1016/j.cct.2021.106394.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineDelivery of Health Care, IntegratedHumansNeoplasm Recurrence, LocalOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid use disorderInfectious disease treatmentUse disordersCo-occurring opioid use disorderTreatment of OUDLife-threatening infectious diseaseSubstantial healthcare utilizationProportion of patientsInfectious disease specialistsInjection drug usePrimary outcome measureIntegrated care modelDisease treatmentMulti-site trialInjectable buprenorphineOpioid useSecondary outcomesHealthcare utilizationInfection morbidityDisease specialistsMedication treatmentSerious infectionsMonthly formulationDrug overdoseID specialists
2020
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder
Cioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. Journal Of Substance Use And Addiction Treatment 2020, 119: 108146. PMID: 33138929, PMCID: PMC7609980, DOI: 10.1016/j.jsat.2020.108146.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineHumansMethadoneNaltrexoneOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid use disorderOpioid epidemicProvider perspectivesUse disordersSystematic reviewType of MOUDExtended-release naltrexoneNumber of patientsOutcomes of interestPubMed database searchReview eligibility criteriaPatient themesPublic health crisisPatient retentionMOUDEligibility criteriaPatientsProviders' perceptionsFinal reviewLack of trainingMedicationsBuprenorphineNaltrexoneMethadoneHealth crisisThe Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review
Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review. Infectious Disease Clinics Of North America 2020, 34: 559-584. PMID: 32782102, PMCID: PMC7437982, DOI: 10.1016/j.idc.2020.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHepatitis CHumansIncidenceOpioid-Related DisordersPrevalencePrisonersPrisonsRiskSubstance Abuse, IntravenousAddressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics
Springer SA, del Rio C. Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics. Infectious Disease Clinics Of North America 2020, 34: xiii-xiv. PMID: 32782107, PMCID: PMC7414777, DOI: 10.1016/j.idc.2020.06.016.Peer-Reviewed Original ResearchAnalgesics, OpioidCommunicable DiseasesEpidemicsHumansOpioid EpidemicOpioid-Related DisordersSubstance-Related DisordersLessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic
Springer SA, del Rio C. Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic. Infectious Disease Clinics Of North America 2020, 34: 637-647. PMID: 32782106, PMCID: PMC7414693, DOI: 10.1016/j.idc.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHIV InfectionsHumansOpioid EpidemicOpioid-Related DisordersUnited StatesIntegrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics
Springer SA, Merluzzi AP, del Rio C. Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics. JAMA 2020, 324: 37-38. PMID: 32159771, PMCID: PMC7957328, DOI: 10.1001/jama.2020.2559.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCommunicable DiseasesCost ControlDelivery of Health Care, IntegratedEpidemicsFinancial SupportHarm ReductionHealth Services AccessibilityHumansInformation DisseminationNarcotic AntagonistsNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionOpioid-Related DisordersPrior AuthorizationPrisonsProgram EvaluationRural Health ServicesStereotypingTelemedicineUnited StatesUnited States Substance Abuse and Mental Health Services AdministrationA Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?
Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success? American Journal On Addictions 2020, 29: 249-267. PMID: 32346932, PMCID: PMC7377168, DOI: 10.1111/ajad.13051.Peer-Reviewed Original ResearchMeSH KeywordsHumansNarcotic AntagonistsOpioid-Related DisordersOutcome Assessment, Health CareTreatment OutcomeConceptsUrine drug testsOpioid usePrimary outcomeOpioid use disorderTreatment studiesTreatment successUse disordersMedication treatment studiesOpioid treatment outcomesDifferent primary outcomesClinical trialsOpioid outcomesTreatment outcomesInclusion criteriaOutcome measuresLiterature reviewDrug testsOutcomesDisordersTreatmentReviewMedicationsMOUDStudyCliniciansCo-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!
Springer SA, Del Rio C. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Clinical Infectious Diseases 2020, 71: 1723-1725. PMID: 32011653, PMCID: PMC7583407, DOI: 10.1093/cid/ciaa111.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineHepacivirusHepatitis CHumansOpioid-Related DisordersPharmaceutical Preparations